Vetter Adds Flexible Serialization Service to Its Portfolio
Vetter has announced it now offers the option of clearly identifying packaging used for drugs. Vetter's comprehensive and flexible serialization service is in response to stricter guidelines from the regulatory authorities of many countries aimed at combatting counterfeit drugs. Pharma and biotech companies can use Vetter's individually customizable solutions as a basis for their own track-and-trace programs to optimize their supply chain.
The number of counterfeit drugs on the market is growing and has quickly become a serious global challenge, putting patients at considerable risk, and costing the pharmaceutical industry a significant amount of money. Lawmakers and regulatory agencies around the world have responded by creating new guidelines to increase drug safety. Government and industry both agree that the best available solution is tracking and tracing drugs from production to distribution, on through to the dispensary or the pharmacy. The key to reaching that goal is serialization and Track-and-Trace; the distinct identification of the smallest packaging unit with a unique identification number.
In some countries, scuh as Turkey, India, China, and Argentina, regulators are already calling for drugs to be serialized. Many other markets will be following suit in the coming years, including South Korea, Brazil, the US, and the EU. The requirements and specific serialization guidelines however, are country specific, which is why pharmaceutical companies operating internationally need flexible solutions to meet these differing requirements. That is why Vetter offers various options for the serialization of drugs. These include making available different serial number and code formats, interfaces and reports or various aggregation depths. And there are, of course, national differences that must be taken into account. South Korea, for example, expects that by 2015, serialization will be included on the item level, while China follows still another concept, including 1D linear codes as well as aggregation with shipping boxes.
"Our serialization service allows for unique identification of the unit level and transportation packaging," says Thomas Otto, Vetter Managing Director. Therefore, we are providing a flexible response to the stricter demands of official agencies, while at the same time actively contributing to greater drug safety. Our customers benefit additionally from the fact that they can use the new service as a basis for their own track-and-trace program. Transparency in distribution prevents counterfeits, but it also promotes greater efficiency for processes along the supply chain."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance